Abstract
Methicillin (M), nafcillin (N) and oxacillin (Ox) are commonly used antimicrobial agents, but limited prospective data are available about the incidence of their side effects in pediatric patients. Sixty-nine patients (newborn-18 yr) were evaluated prospectively for adverse effects associated with M, N or Ox. Hematologic parameters (hemoglobin, hematocrit, WBC with diff, platelet ct, and reticulocyte ct), hepatic enzymes (SGOT, SGPT) and renal function tests (BUN, serum creatinine and urinalysis) were obtained before the institution of treatment and at frequent intervals (min every 5 d) during the course of therapy. Culture and sensitivity, daily body temp and concomitant drugs were recorded. Three of 28 patients receiving M developed eosinophilia (eos, 705-1547/cu mm) within 5-8 days of therapy. Of 32 patients on N, 2 developed neutropenia (neut, 642-752/cu mm) within 4-13 days of therapy; 3 developed eosinophilia (eos, 1030-2171/cu mm) within 1-4 days of therapy; and 1 developed elevation of liver enzymes (SGOT 179 RFU, SGPT 98 RFU) on day 3 of treatment. Of 9 patients receiving Ox, 1 developed elevation of liver enzymes (SGOT 158 RFU, SGPT 409 RFU) on day 15, and 1 developed neutropenia (neut 684/cu mm) on day 11 of therapy. All laboratory values returned to normal with the discontinuation of therapy. Our data suggest that appropriate laboratory tests should be monitored to detect occurrence of adverse effects to M, N and Ox.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Debolt, S., Nahata, M., Powell, D. et al. 1000 ADVERSE EFFECTS OF METHICILLIN, NAFCILLIN, AND OXACILLIN IN PEDIATRIC PATIENTS: A PROSPECTIVE STUDY. Pediatr Res 15 (Suppl 4), 609 (1981). https://doi.org/10.1203/00006450-198104001-01026
Issue date:
DOI: https://doi.org/10.1203/00006450-198104001-01026
